AGIO

Agios Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · agios.com

$27.56

After hrs $27.20 -0.04%

Mkt Cap $1.6B

52w Low $22.24 22.4% of range 52w High $46.00

50d MA $29.73 200d MA $33.22

P/E (TTM) -4.0x

EV/EBITDA -3.3x

P/B 1.4x

Debt/Equity 0.1x

ROE -38.1%

P/FCF -4.2x

RSI (14) —

ATR (14) —

Beta 0.79

50d MA $29.73

200d MA $33.22

Avg Volume 1.1M

About

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 29, 2026	TNS	-1.81	-1.69	+6.6%	28.05	+0.1%	-0.2%	+0.4%	-1.7%	—	—	—
Feb 12, 2026	TNS	-1.97	-1.85	+6.1%	28.07	+2.3%	-0.4%	-0.9%	-1.8%	+1.8%	+4.2%	—
Oct 30, 2025	TNS	-1.93	-1.78	+7.8%	43.18	-0.7%	+0.1%	-7.1%	-7.4%	-6.2%	-6.6%	—
Jul 31, 2025	TNS	-1.74	-1.93	-10.9%	37.22	+0.1%	-6.0%	-2.8%	-2.7%	+1.3%	-0.4%	—
May 1, 2025	TNS	-1.80	-1.55	+13.9%	30.94	+1.7%	-2.7%	-3.1%	-8.5%	-8.8%	-9.4%	—
Feb 13, 2025	TNS	-1.69	-1.74	-3.0%	33.30	-1.1%	-0.2%	+0.9%	+2.2%	+1.4%	+5.8%	—
Oct 31, 2024	TNS	16.69	4.20	-74.8%	44.43	+1.1%	+1.0%	+0.9%	+5.1%	+16.1%	+24.0%	—
Aug 1, 2024	TNS	-1.58	-1.69	-7.0%	44.50	-5.3%	-1.2%	-4.3%	-4.2%	-4.3%	-1.6%	—
May 2, 2024	TNS	-1.64	-1.45	+11.6%	34.58	+0.9%	-0.1%	-3.9%	-5.1%	-6.1%	-4.8%	—
Feb 15, 2024	TNS	-1.64	-1.72	-4.9%	26.80	-1.5%	-1.1%	+1.1%	+0.0%	+11.1%	+23.1%	—
Nov 2, 2023	TNS	-1.69	-1.64	+3.0%	21.00	+1.0%	+7.1%	+6.8%	+10.7%	+7.1%	+1.7%	—
Aug 3, 2023	TNS	-1.60	-1.51	+5.6%	25.94	-0.7%	-1.9%	-1.5%	+0.2%	+0.5%	+3.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 30	Truist	Maintains	Buy → Buy	—	$28.05	$28.07	+0.1%	-0.2%	+0.4%	—	—	—
Apr 21	BofA Securities	Maintains	Buy → Buy	—	$27.07	$26.84	-0.8%	-2.9%	-1.3%	-4.9%	-6.5%	-9.8%
Apr 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.14	$29.58	-15.8%	-23.0%	-25.2%	-24.0%	-26.8%	-27.9%
Apr 6	JP Morgan	Maintains	Neutral → Neutral	—	$35.20	$35.46	+0.7%	-1.1%	-0.3%	-4.1%	-6.5%	-6.5%
Apr 1	Goldman Sachs	Maintains	Neutral → Neutral	—	$33.83	$33.89	+0.2%	+1.1%	+4.0%	+2.9%	+3.8%	-0.2%
Mar 5	Citigroup	Maintains	Buy → Buy	—	$28.19	$28.14	-0.2%	-1.8%	-2.6%	+1.2%	+0.2%	-0.4%
Feb 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.71	$27.85	+0.5%	+1.3%	+0.9%	+0.4%	-0.5%	+3.1%
Jan 6	JP Morgan	Maintains	Neutral → Neutral	—	$27.45	$27.34	-0.4%	+0.1%	+4.0%	+2.6%	+3.5%	+3.2%
Dec 26	Leerink Partners	Maintains	Outperform → Outperform	—	$29.17	$29.06	-0.4%	-3.9%	-6.9%	-6.3%	-6.7%	-6.8%
Dec 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$24.59	$28.00	+13.9%	+18.6%	+13.9%	+10.5%	+11.1%	+10.7%
Dec 24	Truist	Maintains	Buy → Buy	—	$24.59	$28.00	+13.9%	+18.6%	+13.9%	+10.5%	+11.1%	+10.7%
Dec 24	BofA Securities	Maintains	Buy → Buy	—	$24.59	$28.00	+13.9%	+18.6%	+13.9%	+10.5%	+11.1%	+10.7%
Nov 21	JP Morgan	Maintains	Neutral → Neutral	—	$24.57	$24.66	+0.4%	+2.7%	+7.8%	+15.7%	+18.2%	+18.8%
Nov 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.34	$23.30	+4.3%	+10.0%	+13.0%	+18.6%	+27.3%	+30.0%
Nov 20	RBC Capital	Downgrade	Outperform → Sector Perform	—	$22.34	$23.30	+4.3%	+10.0%	+13.0%	+18.6%	+27.3%	+30.0%
Nov 20	BofA Securities	Maintains	Buy → Buy	—	$22.34	$23.30	+4.3%	+10.0%	+13.0%	+18.6%	+27.3%	+30.0%
Nov 20	Leerink Partners	Upgrade	Market Perform → Outperform	—	$22.34	$23.30	+4.3%	+10.0%	+13.0%	+18.6%	+27.3%	+30.0%
Nov 20	Goldman Sachs	Maintains	Neutral → Neutral	—	$22.34	$23.30	+4.3%	+10.0%	+13.0%	+18.6%	+27.3%	+30.0%
Sep 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.61	$35.00	-13.8%	-11.0%	-11.3%	-10.3%	-11.0%	-12.1%
Jul 28	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$40.00	$39.99	-0.0%	-7.0%	-5.7%	-6.2%	-7.0%	-12.5%
Jul 22	BofA Securities	Maintains	Buy → Buy	—	$39.92	$39.58	-0.9%	-0.7%	+1.6%	-0.7%	+0.2%	-6.8%
May 2	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$30.94	$31.47	+1.7%	-2.7%	-3.1%	-8.5%	-8.8%	-9.4%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$35.22	$36.14	+2.6%	+0.7%	-0.1%	-2.2%	-2.5%	+0.9%
Dec 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$41.96	$42.19	+0.5%	-7.0%	-14.7%	-15.6%	-15.8%	-18.5%
Dec 10	RBC Capital	Maintains	Outperform → Outperform	—	$48.64	$48.65	+0.0%	-5.4%	-10.8%	-21.5%	-19.9%	-12.2%
Dec 9	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$61.64	$56.11	-9.0%	-21.1%	-25.3%	-29.6%	-38.1%	-36.8%
Nov 1	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$44.43	$44.93	+1.1%	+1.0%	+0.9%	+5.1%	+16.1%	+24.0%
Sep 27	Leerink Partners	Downgrade	Outperform → Market Perform	—	$48.05	$45.57	-5.2%	-5.1%	-7.5%	-11.6%	-13.0%	-15.6%
Sep 19	RBC Capital	Maintains	Outperform → Outperform	—	$45.54	$46.82	+2.8%	+4.0%	+2.2%	+0.5%	+2.3%	+7.7%
Aug 2	RBC Capital	Maintains	Outperform → Outperform	—	$44.50	$42.14	-5.3%	-1.2%	-4.3%	-4.2%	-4.3%	-1.6%
Jun 4	RBC Capital	Maintains	Outperform → Outperform	—	$43.83	$44.05	+0.5%	+8.0%	+11.4%	+9.1%	+8.6%	+7.7%
Jun 4	Goldman Sachs	Maintains	Neutral → Neutral	—	$43.83	$44.05	+0.5%	+8.0%	+11.4%	+9.1%	+8.6%	+7.7%
May 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$34.58	$34.90	+0.9%	-0.1%	-3.9%	-5.1%	-6.1%	-4.8%
Feb 23	JP Morgan	Maintains	Neutral → Neutral	—	$29.78	$29.87	+0.3%	+10.8%	+10.4%	+16.9%	+13.1%	+8.5%
Feb 16	RBC Capital	Maintains	Outperform → Outperform	—	$26.80	$26.41	-1.5%	-1.1%	+1.1%	+0.0%	+11.1%	+23.1%
Nov 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$21.00	$21.20	+1.0%	+7.1%	+6.8%	+10.7%	+7.1%	+1.7%
Aug 7	JP Morgan	Maintains	Neutral → Neutral	—	$25.46	$25.46	+0.0%	+0.4%	+2.1%	+2.4%	+5.2%	+4.7%
Jun 27	RBC Capital	Maintains	Outperform → Outperform	—	$27.47	$27.92	+1.6%	+2.4%	+6.3%	-0.1%	+3.1%	+2.6%
Feb 3	Piper Sandler	Maintains	Overweight → Overweight	—	$30.18	$30.40	+0.7%	+0.1%	+0.5%	+2.5%	-2.4%	-4.6%
Dec 1	JP Morgan	Maintains	Neutral → Neutral	—	$30.14	$29.93	-0.7%	-2.5%	+4.6%	-1.1%	-5.1%	-7.3%
Nov 17	Goldman Sachs	Upgrade	Sell → Neutral	—	$27.13	$27.92	+2.9%	+5.4%	+4.0%	+7.0%	+5.7%	+6.3%
Aug 5	SVB Leerink	Maintains	Outperform → Outperform	—	$28.61	$27.82	-2.8%	+3.9%	+2.7%	-4.3%	-1.4%	-9.2%
Jul 27	SVB Leerink	Upgrade	Market Perform → Outperform	—	$19.51	$20.59	+5.5%	+10.8%	+10.3%	+10.6%	+9.1%	+17.6%
May 24	Goldman Sachs	Maintains	Sell → Sell	—	$21.09	$20.52	-2.7%	-7.7%	-6.9%	-8.1%	-6.0%	-7.7%
May 17	SVB Leerink	Maintains	Market Perform → Market Perform	—	$22.14	$22.98	+3.8%	+0.9%	-4.5%	-6.9%	-4.7%	-4.7%
Mar 7	Goldman Sachs	Maintains	Sell → Sell	—	$31.53	$31.45	-0.3%	-1.9%	-2.7%	-0.0%	-0.3%	-9.0%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.26	$32.43	+0.5%	-0.4%	-2.3%	-4.1%	-4.9%	-2.3%
Feb 25	RBC Capital	Maintains	Outperform → Outperform	—	$29.13	$29.11	-0.1%	+5.7%	+6.9%	+10.5%	+10.7%	+10.3%
Feb 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.55	$27.12	-1.6%	+5.7%	+11.8%	+13.0%	+16.9%	+17.1%
Feb 22	SVB Leerink	Maintains	Market Perform → Market Perform	—	$29.42	$28.58	-2.9%	-1.9%	-6.4%	-1.0%	+4.7%	+5.8%

Recent Filings

8-K

Agios Pharmaceuticals, Inc. -- 8-K Filing

Agios Pharmaceuticals is gaining momentum with AQVESME's thalassemia launch showing early traction and a planned sickle cell sNDA submission positioning the company for multiple clinical and commercial catalysts throughout 2026.

Apr 29

8-K

Agios Pharmaceuticals, Inc. -- 8-K Filing

Agios Pharmaceuticals' FDA-approved AQVESME achieved $54 million annual revenue while advancing mitapivat into sickle cell disease trials, supported by $1.2 billion in cash reserves.

Feb 12

Data updated apr 24, 2026 4:33pm · Source: massive.com